Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report.
10.4048/jbc.2011.14.2.135
- Author:
Changhoon YOO
1
;
Sung Bae KIM
;
Jin Hee AHN
;
Kyung Hae JUNG
;
Yongchel AHN
;
Gyungyub GONG
;
Hak Hee KIM
;
Hee Jung KIM
;
Byung Ho SON
;
Sei Hyun AHN
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. sbkim3@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Endocrine therapy;
Fulvestrant
- MeSH:
Breast;
Breast Neoplasms;
Estradiol;
Estrogens;
Female;
Follow-Up Studies;
Humans;
Injections, Intramuscular;
Korea;
Retrospective Studies
- From:Journal of Breast Cancer
2011;14(2):135-139
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Fulvestrant, a potent estrogen receptor (ER) antagonist with a novel mechanism of action, has shown efficacy in pretreated patients with advanced breast cancer. We assessed the efficacy and tolerability of fulvestrant in Korean postmenopausal women. METHODS: Of the 25 candidates identified at Asan Medical Center, Seoul, Korea, six were deemed ineligible due to inadequate baseline and follow-up imaging. The 19 patients included in this retrospective analysis received the approved dose of fulvestrant (250 mg intramuscular injection, once per month) as second- (n=8), third- (n=7), or fourth-line (n=4) endocrine therapy. RESULTS: At a median follow-up of 7.4 months (range, 1.2-34.8 months), the 19 patients received a median of four cycles (range, 1-34 cycles) of fulvestrant. Median time to progression was 5.5 months (95% confidence interval [CI], 0.4-10.7 months), and median overall survival was 17.9 months (95% CI, 2.7-33.1 months). Among 17 evaluable patients, one (5.3%) achieved a partial response, 10 (52.6%) showed stable disease, and six (31.6%) showed progressive disease. The clinical benefit rate was 26.3%. Four patients (21.1%) reported adverse events, but all were grade 1 or 2. CONCLUSION: Fulvestrant was effective and well tolerated in patients with advanced breast cancer who had been previously treated with several lines of endocrine and chemotherapeutic agents.
